All In Biotech

Drug Trial Radar · NCT00380575

Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Aug 2000

Primary completion

Not stated

Study completion Feb 2003

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Astellas Pharma US, Inc.
First posted
Sep 26, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.

Conditions

  • Hyponatremia

Interventions

  • YM087Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy outcome will be change from baseline in serum sodium over the duration of treatment. The primary safety outcome will be safety parameters (e.g., adverse events, vital signs, EGG, laboratory measurements).

Locations

47 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tuscon, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Miami, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Springfield, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Worchester, Massachusetts

  • Site not named

    Petoskey, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Rolla, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    New York, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Columbia, South Carolina

  • Site not named

    Sioux Falls, South Dakota

  • Site not named

    Chattanooga, Tennessee

  • Site not named

    Norfolk, Virginia

  • Site not named

    Salem, Virginia

  • Site not named

    Huntington, West Virginia

  • Site not named

    Madison, Wisconsin

  • Site not named

    Drummondville, Quebec, Canada

  • Site not named

    Montreal 2 Sites, Quebec, Canada

  • Site not named

    Ashkelon, Israel

  • Site not named

    Beersheba, Israel

  • Site not named

    Haifa 2 Sites, Israel

  • Site not named

    Holon, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Rehovot, Israel

  • Site not named

    Safed, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Tel HaShomer, Israel

  • Site not named

    Bloemfontein, South Africa

  • Site not named

    Buff, South Africa

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.